Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Direct molecular mimicry enables off-target cardiovascular toxicity by an enhanced affinity TCR designed for cancer immunotherapy

Raman, Marine C. C., Rizkallah, Pierre ORCID: https://orcid.org/0000-0002-9290-0369, Simmons, Ruth, Donnellan, Zoe, Dukes, Joseph, Bossi, Giovanna, Le Provost, Gabrielle S., Todorov, Penio, Baston, Emma, Hickman, Emma, Mahon, Tara, Hassan, Namir, Vuidepot, Annelise, Sami, Malkit, Cole, David ORCID: https://orcid.org/0000-0003-0028-9396 and Jakobsen, Bent K. 2016. Direct molecular mimicry enables off-target cardiovascular toxicity by an enhanced affinity TCR designed for cancer immunotherapy. Scientific Reports 6 , 18851. 10.1038/srep18851

[thumbnail of raman et al 2016.pdf]
Preview
PDF - Published Version
Download (2MB) | Preview

Abstract

Natural T-cell responses generally lack the potency to eradicate cancer. Enhanced affinity T-cell receptors (TCRs) provide an ideal approach to target cancer cells, with emerging clinical data showing significant promise. Nevertheless, the risk of off target reactivity remains a key concern, as exemplified in a recent clinical report describing fatal cardiac toxicity, following administration of MAGE-A3 specific TCR-engineered T-cells, mediated through cross-reactivity with an unrelated epitope from the Titin protein presented on cardiac tissue. Here, we investigated the structural mechanism enabling TCR cross-recognition of MAGE-A3 and Titin, and applied the resulting data to rationally design mutants with improved antigen discrimination, providing a proof-of-concept strategy for altering the fine specificity of a TCR towards an intended target antigen. This study represents the first example of direct molecular mimicry leading to clinically relevant fatal toxicity, mediated by a modified enhanced affinity TCR designed for cancer immunotherapy. Furthermore, these data demonstrate that self-antigens that are expressed at high levels on healthy tissue should be treated with extreme caution when designing immuno-therapeutics.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Subjects: R Medicine > R Medicine (General)
Publisher: Nature Publishing Group
ISSN: 2045-2322
Funders: Wellcome
Date of First Compliant Deposit: 30 March 2016
Date of Acceptance: 27 November 2015
Last Modified: 04 May 2023 05:06
URI: https://orca.cardiff.ac.uk/id/eprint/86283

Citation Data

Cited 60 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item

Downloads

Downloads per month over past year

View more statistics